SavedAdd your journal

Journals / European Journal of Rheumatology / 2014 / Cilt: 1 - Sayı: 4

Severe candida laryngitis in a patient with rheumatoid arthritis treated with adalimumab

Oğuz GÜÇLÜ
Hatice YILMAZ
Zerrin ÖĞRETMEN
Şenol KOBAK
Pages
167–169
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rheumatoid arthritis is a chronic erosive rheumatic disease that can present with polyarticular involvement.
📊
Key Findings & Data:In this report, we report a 52-year-old male patient using adalimumab for active rheumatoid arthritis who presented to our polyclinic with generalized mouth and throat sores, hoarseness, and swallowing difficulty.
💡
Conclusion & Impact:Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rheumatoid arthritis is a chronic erosive rheumatic disease that can present with polyarticular involvement. Anti-TNF-alpha drugs are used in cases that are resistant to traditional disease-modifying antirheumatic drugs (DMARDs). Anti-TNF-alpha drugs are groundbreaking drugs, the efficacy of which has been proven in the treatment of rheumatoid arthritis. However, the data concerning safety remain limited and contradictory. The risk of tuberculosis reactivation, various infections, as well as lymphoproliferative disease and/or secondary malignancy is a matter of discussion. In this report, we report a 52-year-old male patient using adalimumab for active rheumatoid arthritis who presented to our polyclinic with generalized mouth and throat sores, hoarseness, and swallowing difficulty. Candida laryngitis was detected in the laryngoscopy and culture samples. Adalimumab was discontinued, and the infection was controlled with anti-fungal treatment

🔖

Cite This Article

GÜÇLÜ, O., YILMAZ, H., ÖĞRETMEN, Z., KOBAK, Ş. (2022). Severe candida laryngitis in a patient with rheumatoid arthritis treated with adalimumab. European Journal of Rheumatology, Cilt: 1 - Sayı: 4, 167–169. https://ajindex.com/articles/511877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necro- sis factor agents and tuberculosis risk: mecha- nisms of action and clinical management. Lan- cet Infect Dis 2003
  2. [CrossRef] Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD
  3. Biobadaser Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter ac- tive-surveillance report. Arthritis Rheum 2003, 48: 2122-7. [CrossRef] 168 Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, et al. Updated consen- sus statement on biological agents for the treat- ment of rheumatic diseases, 2008. Ann Rheum Dis 2008
  4. . 67 Suppl 3: p. iii2-25. [CrossRef] Jassal, MS, Bishai WR. The risk of infections with tumor necrosis factor-alpha inhibitors. J Clin Rheumatol 2009
  5. [CrossRef] Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional com- parisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002
  6. [CrossRef] Lügering A1, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a cas- pase-dependent pathway. Gastroenterology 2001
  7. [CrossRef] Warris, A, Bjorneklett A, Gaustad P. Invasive pulmo- nary aspergillosis associated with infliximab ther- apy. N Engl J Med, 2001
  8. [CrossRef] Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threat- ening histoplasmosis complicating immuno- therapy with tumor necrosis factor alpha an- tagonists infliximab and etanercept. Arthritis Rheum 2002
  9. [CrossRef] van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zand- stra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infec- tion in a patient with infliximab and methotrexate. Intensive Care Med 2003
  10. [CrossRef] Tsiodras S, Samonis G, Boumpas DT, Kontoyian- nis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008
  11. [CrossRef] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized control